IL2 and neoplasm: Furthermore, bempegaldesleukin (NKTR-214, an immunostimulatory IL-2 prodrug), which is competent in activating and continuously expanding CD4+ T and CD8+ T cells, manifests a synergistic anti-tumor effect when combined with ICIs.